Soru

Zorluk: OrtaPharmacologic Interventions

A 71-year-old man presents to the primary care clinic reporting intense pain and swelling in his right big toe that began abruptly overnight. He states the pain is so severe that he cannot bear weight on his foot or tolerate the touch of a bedsheet. His medical history is significant for ischemic cardiomyopathy with a left ventricular ejection fraction of 30%30\%, stage 4 chronic kidney disease with a baseline estimated glomerular filtration rate of 24 mL/min/1.73 m224 \text{ mL/min/1.73 m}^2, and a hospitalized episode of bleeding peptic ulcer disease three years ago. His current daily medications include carvedilol, sacubitril-valsartan, and low-dose aspirin. Vital signs are temperature 37.2∘C37.2^\circ\text{C} (99.0∘F99.0^\circ\text{F}), blood pressure 118/76 mmHg118/76\text{ mmHg}, and heart rate 78/min78\text{/min}. Physical examination reveals a markedly erythematous, warm, swollen, and exquisitely tender first metatarsophalangeal joint on the right foot. The remainder of the joint examination is unremarkable. Which of the following is the most appropriate initial pharmacologic intervention for this patient's acute joint pain?

  1. Intra-articular triamcinoloneCevap
  2. B
    Oral indomethacin
  3. C
    Oral colchicine
  4. D
    Oral prednisone
  5. E
    Oral allopurinol

Cevap

Intra-articular triamcinolone is the most appropriate initial therapy because it provides targeted relief for a monoarticular flare while bypassing the severe systemic risks associated with other agents in a patient with chronic kidney disease, heart failure, and prior peptic ulcer disease.
Intra-articular glucocorticoid injection (e.g., triamcinolone) is the safest and most effective treatment for an acute gout flare localized to 1 or 2 easily accessible joints (such as the first metatarsophalangeal joint) in patients with multiple medical comorbidities. This patient has stage 4 chronic kidney disease, severe heart failure with reduced ejection fraction, and a history of peptic ulcer disease. These conditions present absolute or severe relative contraindications to all first-line systemic therapies for acute gout. Local administration provides rapid anti-inflammatory action within the joint space while minimizing systemic absorption, thereby avoiding nephrotoxicity, fluid retention, and gastrointestinal irritation.

Adım Adım Çözüm

1
Diagnose the acute condition based on the clinical presentation.
The patient has acute monoarticular arthritis of the first metatarsophalangeal joint (podagra), which is classic for an acute gout flare.
Establishing the acute problem is required before selecting pharmacotherapy.
2
Review the patient's medical history for contraindications to standard gout therapies.
The patient has stage 4 chronic kidney disease, ischemic cardiomyopathy with a severely reduced ejection fraction, and a history of peptic ulcer bleeding.
Gout medications have strict contraindications that are frequently tested. Comorbidities dictate the safe treatment path.
3
Evaluate the safety profile of each pharmacological option against the identified comorbidities.
NSAIDs and colchicine are unsafe due to renal impairment and bleeding risk. Systemic steroids are unsafe due to the severe heart failure. Intra-articular steroids remain the only safe option.
To select the single best intervention by process of elimination.

Anahtar Kavram

Management of acute gout in patients with multiple comorbidities often requires localized therapy (intra-articular glucocorticoids) to avoid the systemic contraindications of NSAIDs, colchicine, and oral glucocorticoids.
Tahmini Süre:1m 15s
Bu soruyu puanla